LOGIN
ID
PW
MemberShip
2025-09-19 14:19
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
How will fate fare for Roche¡¯s two anticancer drugs?
by
Eo, Yun-Ho
Sep 1, 2025 06:05am
The industry¡¯s eyes are on whether Roche's two anti-cancer drugs, which have faced repeated failures, will succeed in securing reimbursement listing this time. According to industry sources, Roche Korea's treatment for refractory diffuse large B-cell lymphoma(DLBCL), ¡®Polivy (polatuzumab vedotin)¡¯ and the PD-L1 inhibitor-based immunoth
Opinion
[Reporter's View] New opportunities have emerged for K-Bio
by
Son, Hyung Min
Sep 1, 2025 06:04am
In the global antibody-drug conjugate (ADC) market, the rapid rise of Chinese pharmaceutical companies is being noticed. Just five to six years ago, China was considered a 'technology follower.' However, with massive capital and swift clinical development, it has quickly become a key player in the global market. Chinese pharmaceutical com
Company
COVID-19 response more important for high-risk groups
by
Whang, byung-woo
Sep 1, 2025 06:04am
While COVID-19 has entered an endemic phase and become a resident disease in daily life, it remains a significant threat to high-risk groups like the elderly. In fact, the outbreak of COVID-19, which had slowed down for a while, has been showing an upward trend again. According to the Korea Disease Control and Prevention Agency's Infectious D
Company
Capvaxive release imminent in the pneumococcal vaccine mkt
by
Whang, byung-woo
Sep 1, 2025 06:03am
MSD's adult-specific 21-valent protein-conjugated vaccine Capvaxive was granted marketing authorization in Korea by the Ministry of Food and Drug Safety and has emerged as a new competitor in the domestic adult pneumococcal vaccine market. With Prevenar 20 now launched in the market previously contested by Prevenar 13 and Vaxneuvance, Capvaxi
Company
CKD says, "New ADC drug enters first clinical trials"
by
Son, Hyung Min
Sep 1, 2025 06:03am
Chong Kun Dang is accelerating its development of a new c-Met-targeted Antibody-Drug Conjugate (ADC). With its newly entered clinical candidate, 'CKD-703,' the company is aiming to secure a best-in-class ADC and is seeking a differentiated strategy in a globally competitive landscape. On August 29, Samsung Medical Center and Aimed Bio co-
Policy
Industry requests incentives for rare and orphan drug supply
by
Lee, Hye-Kyung
Aug 29, 2025 06:07am
The pharmaceutical industry has voiced the need for incentives to expand supply support, such as official certification, for companies supplying rare and essential drugs. The Ministry of Food and Drug Safety (MFDS, Minister Yu-kyoung Oh) visited the Korea Orphan & Essential Drug Center on the 28th to review the center's current projects s
Company
Ozempic adds indication for patients with diabetes and CKD
by
Son, Hyung Min
Aug 29, 2025 06:07am
Novo Nordisk Korea (General Manager: Kasper Roseeuw Poulsen) announced on the 28th that Ozempic has been approved as a treatment for type 2 diabetes with chronic kidney disease. With this approval, Ozempic is now indicated for: ¡ã Use as an adjunct to a two-drug regimen (either alone or in combination with other diabetes medications), in
Opinion
[Reporter's View] Innovativeness and trust in healthcare AI
by
Whang, byung-woo
Aug 29, 2025 06:07am
As the innovation of Artificial Intelligence (AI) is robustly developed in the healthcare sector, concerns related to both utilization and implementation are arising. In Korea, the cost required for AI utilization in medical institutions is considered the number one priority for discussion. Additionally, 'awareness' has also been brought
Policy
Next year¡¯s reimb reevaluations to be discussed further
by
Lee, Tak-Sun
Aug 29, 2025 06:07am
The government has decided to continue discussions on the 2026 reimbursement adequacy reevaluation plan. While the reevaluation was initially expected to be approved this month through the Health Insurance Policy Deliberation Committee review, it is reported that disagreements remain unresolved regarding selection criteria, procedural i
Company
Eylea high-dosage PFS formulation wins nod in Korea
by
Whang, byung-woo
Aug 29, 2025 06:04am
Bayer Korea announced on August 28 that it has received domestic approval for 'Eylea PFS 8mg (aflibercept),' a pre-filled syringe formulation, from the Ministry of Food and Drug Safety (MFDS). The indication for 'Eylea PFS 8mg' has been approved the same as that for the existing Eylea vial formulation. Now, it can be administered more sim
1
2
3
4
5
6
7
8
9
10
>